Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jan 26, 2021 9:45 AM - Jan 28, 2021 5:00 PM

(US Eastern Standard Time)

Pharmacovigilance and Risk Management Strategies Conference

Session 4: Assessing the Impact of COVID and Implications for Pharmacovigilance in the Future

Session Chair(s)

Sarah  Vaughan

Sarah Vaughan

Head of Vigilance Operations

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

During 2020, the COVID-19 pandemic has created numerous challenges and opportunities across the healthcare landscape. Regulatory authorities have provided emerging guidance during the pandemic that has the potential to impact ongoing regulatory expectations. This session will begin with a review of the key challenges experienced and the initial industry response, followed by a regulatory overview of current COVID-related data collection requirements and its impact on post-marketing surveillance. This session will also explore several operational strategies that have proved successful and warrant long-term consideration. Lastly, participants will be invited to engage in a dialogue on the future implications for pharmacovigilance.

Learning Objective :
  • Identify the key challenges faced by pharmacovigilance departments while operating during the COVID pandemic
  • Describe the relevant regulatory requirements related to COVID data collection and understand their wider impact
  • Detail the operational impacts across the three vital pillars (people, process and technology) of every pharmacovigilance organization and highlight opportunities for future efficiencies

Speaker(s)

Vita M. Petrik, BSN

AstraZeneca Vaccine Plan An Extraordinary Opportunity

Vita M. Petrik, BSN

Astrazeneca Pharmaceuticals, United States

Senior Director, PV Processes, Partnerships and Contracts

Kendal  Harrison

A Regulatory Perspective on COVID Data Collection & Its Impact on Post Marketing-surveillance

Kendal Harrison

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Pandemic Systems Delivery Manager

Annette S. Williams, MBA, RPh

The Operational Realities and Benefits of the COVID Era

Annette S. Williams, MBA, RPh

IQVIA, United States

Vice President, Pharmacovigilance

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.